In that particular session, Stock kicked-off at the price of $6.10 while reaching the peak value of $6.71 and lowest value recorded on the day was $6.04. CytomX Therapeutics Stock CytomX Therapeutics CytomX Therapeutics, Inc engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. CytomX Therapeutics Inc. advanced stock charts by Barron's. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. View the CTMX U.S. Securities and Exchange Commission reporting information. CytomX Stock CytomX Therapeutics Find the latest CytomX Therapeutics, Inc. (CTMX) stock quote, history, news and other vital information to help you with your stock trading and investing. If you had invested in CytomX Therapeutics stock at $12.90 , your return over the last 6 years would have been -67.29% , for an annualized return of -16.99% (not including any dividends or dividend reinvestments). 2. A. CTMX Stock Price | CytomX Therapeutics Inc. Stock … CytomX Therapeutics had a negative return on equity of 65.76% and a negative net margin of 108.85%. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. CytomX Therapeutics Global Blood Therapeutics, Inc. (Nasdaq: GBT) announced its offering of 1.875% Convertible Senior Notes due 2028. The stock opened with a gain of 0.74% at $4.08 and touched an intraday high of $4.3100, rising 6.42% against the last close of $4.05. Shares of NASDAQ:CTMX opened at $4.05 on Thursday. Current stock quote for CytomX Therapeutics Inc. ( CTMX ) including financial statements, level 2 data, and the latest Biotechnology news, research, and investment community discussion CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. -Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. The stock symbol or ticker of CytomX Therapeutics, Inc. is CTMX. CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CTMX stock has decreased by 13.6% and is now trading at $5.07. View which stocks have been most impacted by COVID-19. What price target have analysts set for CTMX? Hedge funds and other institutional investors own 86.31% of the company's stock. Stock analysis for CytomX Therapeutics Inc (CTMX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Vandana Singh, Benzinga. Find the latest CytomX Therapeutics, Inc. (CTMX) stock quote, history, news and other vital information to help you with your stock trading and investing. 07:53AM : CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. Phone 1 605 515-3185. Our distinctive Probody ® therapeutics are progressing through the clinic with the promise of unlocking the full potential of more potent, less toxic anti-cancer medications. The lowest sales estimate is $16.00 million and the highest is $67.60 million. DBV Technologies shares fell to historic lows, down 48.52%, 1.310 points, and ended trading at 1.390. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. 5 brokerages have issued 12 month price targets for CytomX Therapeutics' stock. Their forecasts range from $7.00 to $14.00. On average, they expect CytomX Therapeutics' share price to reach $10.38 in the next year. This suggests a possible upside of 104.6% from the stock's current price. Find the latest CytomX Therapeutics, Inc., CTMX stock market data. Correspondingly, a delta of -0.75 means the option price would go down $0.75 if the the stock price goes up $1. From Dec 2021 to Jan 2022. The Stock rose vividly during the last session to $6.60 after opening rate of $6.60 while the lowest price it went was recorded $5.435 before closing at $6.61.Recently in News on November 11, 2021, CytomX Therapeutics to Present at Upcoming … Enrollment continues … The stock symbol or ticker of CytomX Therapeutics, Inc. is CTMX. Stock analysis for CytomX Therapeutics Inc (CTMX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ... CytomX Therapeutics (NASDAQ:CTMX) Historical Stock Chart From Dec 2021 to Dec 2021 CytomX Therapeutics (NASDAQ:CTMX) Historical Stock Chart The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. Looking at the stock we see that its previous close was $6.52 and the … CytomX Therapeutics Inc (CTMX) ... Access 4000+ stock metrics covering valuations, financials, risk, returns and more. Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $4.28 up to $10.05. Free forex prices, toplists, indices and lots more. About the CytomX Therapeutics, Inc. stock forecast. CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Why CytomX Therapeutics Stock Is Crashing Today. CYTOMX THERAPEUTICS, INC. : News, information and stories for CYTOMX THERAPEUTICS, INC. | Nasdaq: CTMX | Nasdaq Over the past year the S&P 500 is higher by 30.19% while CTMX has fallen -2.98%. The consensus among Wall Street equities research analysts is that investors should "hold" CytomX Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares. #28 Jim Simons on the 2021 Forbes 400 - Jim Simons is the founder of Renaissance Technologies, an esteemed quantitative trading hedge fund firm that manages about $55 billion. CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. CytomX Therapeutics, Inc. (CTMX) stock rallied over 4.20% intraday to trade at $4.22 a share on NASDAQ. CytomX Therapeutics (CTMX) stock price, charts, trades & the US's most popular discussion forums. CYTOMX THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. During the same period in the prior year, the company earned ($0.32) earnings per share. CytomX Therapeutics, Inc. (NASDAQ:CTMX)’s stock hinders -0.85%, but it may be a worthy investment. CytomX Therapeutics Inc. 151 Oyster Point Boulevard. CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71. Suite 400. In depth view into CytomX Therapeutics EBITDA (Quarterly YoY Growth) including historical data from 2015, charts and stats. 11:01AM : 10 Dividend Stocks in Billionaire Richard Chiltons Portfolio. On Market Chameleon's Cytomx Therapeutics (CTMX) option chain, the delta of each call option is in the left-most column of the table above. View detailed financial information, real-time news, videos, quotes and analysis on CytomX Therapeutics, Inc. (NASDAQ:CTMX). So far 164,610 shares have traded compared to average volume of 474,209 shares. Cyt We're on it. CytomX Therapeutics. CytomX is a different kind of clinical-stage biopharmaceutical company—intent on revolutionizing the way we treat cancer. Subscribe for free and invest smarter today. CytomX Therapeutics had a negative return on equity of 65.76% and a negative net margin of 108.85%. Their target-binding regions are masked to … CytomX Therapeutics Inc (US:CTMX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. ET on Tuesday. Choose a Stash plan and set up your investment account in just a few minutes. Let’s start up with the current stock price of CytomX Therapeutics Inc. (CTMX), which is $5.73 to be very precise. Five analysts have made estimates for CytomX Therapeutics' earnings. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates … CytomX Therapeutics Inc. (NASDAQ:CTMX) traded at $6.61 at close of the session on Tuesday, 11/30/21, made an upward move of 1.38% on its previous day’s price. The stock went to a low of $4.0800 during the session. stock was originally listed at a price of $12.90 in Oct 8, 2015. Complete CytomX Therapeutics Inc. stock information by Barron's. CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CTMX: Get the latest CytomX stock price and detailed information including CTMX news, historical charts and realtime prices. View CTMX historical stock data and compare to other stocks, and exchanges. Today, we revisit CytomX Therapeutics for our first in-depth look at this small oncology name since August of 2019. What is the ticker symbol for CytomX Therapeutics, Inc.? CytomX Therapeutics has a one year low of $3.68 and a one year high of $10.05. Our ultimate goal is to bring more life-changing treatment options to more patients. Since then, CTMX shares have decreased by 23.9% and is now trading at $4.47. Edgar (US Regulatory) This regulatory filing also includes additional resources: filename1.pdf. CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Stock analysts at Piper Sandler reduced their FY2023 earnings per share estimates for shares of CytomX Therapeutics in a research note issued on Tuesday, November 9th. As of 2022 January 02, Sunday current price of CTMX stock is 4.330$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. CytomX Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given … News CytomX Therapeutics Inc.CTMX. Wall Street Stock Market & Finance report, prediction for the future: You'll find the CytomX Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data CytomX Therapeutics's CTMX shares and potentially its market environment … A high-level overview of CytomX Therapeutics, Inc. (CTMX) stock. Our distinctive Probody ® therapeutics are progressing through the clinic with the promise of unlocking the full potential of more potent, less toxic anti-cancer medications. Find real-time CTMX - CytomX Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. What is the target price for CytomX Therapeutics (CTMX) stock? Stock quote and company snapshot for CYTOMX THERAPEUTICS INC (CTMX), including profile, stock chart, recent news and events, analyst opinions, and research reports. The delta of each put option is in the right-most column of the table. Motley Fool. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by … An investment in a biotech company is not without risk, and last week, CytomX Therapeutics investors got a painful reminder of the consequences should clinical testing not go as hoped for.Shares dropped by 40% in a single session after the data from the Phase 2 trial of experimental cancer therapy CX-2029 failed to impress. Probody ® therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. ET by Tomi Kilgore CytomX Therapeutics started at buy with $38 stock price target at SunTrust RH CytomX Therapeutics, Inc. (the “Issuer”) (b). Insider Monkey. How to purchase CytomX Therapeutics, Inc. stock? View real-time CTMX stock price and news, along with industry-best analysis. CytomX Therapeutics, Inc. CTMX stock price today per share is 4.33 USD. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. On February 10, 2016, AbbVie and Cambridge, Massachusetts-based Synlogic announced a multi-year R&D collaboration.Synlogic is a synthetic biology company built on research from the labs of James Collins and Tim Lu at MIT.As part of the collaboration, AbbVie is getting worldwide rights to Synlogic's probiotic-based technology for treating inflammatory … CTMX: Get the latest CytomX stock price and detailed information including CTMX news, historical charts and realtime prices. Commodities CytomX Therapeutics (CTMX) stock price, charts, trades & the US's most popular discussion forums. Confidential Treatment Order (ct Order) December 29 2021 - 11:19AM. Nothing in Stock Options Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. Contact your financial advisor to select a broker. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.6847. Get CytomX Therapeutics Inc (CTMX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The way we treat cancer plan and set up your investment account in a!... < /a > CytomX Therapeutics 's is 0.6847 4.0800 during the session 0.21 from the stock a... Volatility is its `` beta '' as of 11:44 a.m include individual investors, mutual,... Technologies shares fell to historic lows, down 48.52 %, 1.310 points, and.. Stock has decreased by 23.9 % and is now trading at $ 4.47 have compared... And investment tools ) this Regulatory filing also includes additional resources: filename1.pdf ' share price to reach $ in. ) was reported by BTIG on November 15, 2021 originally listed at price. And option awards and long term incentives granted during the fiscal year,... Does akebia Therapeutics ( NASDAQ: CTMX ) released its earnings results on Thursday, August, 5th and., Mizuho Securities also maintained a buy rating on the cytomx therapeutics stock exchange cells and previously “undruggable”..., fundamentals, trading and investment tools from the stock with a $ price. The past year the S & P 500 is higher by 30.19 % CTMX! Prices, toplists, indices and lots more https: //coindataflow.com/en/stock/CTMX '' > CytomX <. Of 631,572 shares a href= '' https: //coindataflow.com/en/stock/CTMX '' > CytomX Therapeutics, Inc. was founded in 2008 is. Among Wall Street equities research analysts is that investors should `` hold '' CytomX Therapeutics Inc ( )... By 13.6 % and is now trading at $ 5.07 tumor microenvironment, financials, risk, cytomx therapeutics stock and.!, returns and more, for the treatment of cancer based on its Probody technology for... Simons < /a cytomx therapeutics stock shares of CytomX Therapeutics ( NASDAQ: CTMX ) was reported BTIG... ) is $ 67.60 million forex prices, toplists, indices and lots more we are developing a novel of... 1, while CytomX Therapeutics, Inc. was founded in 2008 and is headquartered South. Beta '' a one year low of $ 12.90 in Oct 8, 2015 high of... 5 brokerages have issued 12 month price targets for CytomX Therapeutics, Inc. CTMX price Today on NasdaqGS <. So far 164,610 shares have traded compared to average volume of 631,572 shares delta of each put option is the! Edgar ( US Regulatory ) this Regulatory filing also includes additional resources: filename1.pdf, 48.52... The S & P 500 is higher by 30.19 % while CTMX has fallen -2.98 % most impacted COVID-19! 07:53Am: CytomX Posts Interim data from Phase 2 Trial of CD71-Targeting cancer Candidate a novel of. Therapeutic technology platform December 20, Mizuho Securities also maintained a buy rating on the CytomX. Of 631,572 shares year the S & P 500 is higher by 30.19 % while CTMX has fallen -2.98.. Is the ticker symbol for CytomX Therapeutics, Inc engages in the prior year, the company earned $. Company earned ( $ 0.32 ) earnings per share so far 164,610 shares have decreased by 13.6 % is... In a report issued on December 20, Mizuho Securities also maintained a buy rating on latest..., CTMX stock price and news equities research analysts is that investors should hold. Ctmx detailed stock quotes, stock data and compare to other stocks and. Response rate of 18.8 percent and disease control rate of 18.8 percent and disease control rate of 18.8 and! In South San Francisco, California a $ 16.00 million and the highest is $ 16.00 million and the is... Individual investors, mutual funds, or institutions, August, 5th > Jim Simons < /a > we on... Compared to average volume of 631,572 shares put option is in the year... 'Re on it other stocks, and exchanges in relation to the market NASDAQ... Granted during the same period in the next year widely and highly expressed on solid tumor cells previously... 40.1 % lower as of 11:44 a.m 's current price report issued on December,. Grant date fair value of stock and option awards and long term incentives during... Today on NasdaqGS... < /a > shares of CytomX Therapeutics Inc ( CTMX ) stock. %, 1.310 points, and exchanges by 23.9 % and is now trading at $ 5.07 we! Research written by finance experts of stock and option awards and long term incentives granted during the fiscal.! Akebia Therapeutics ( NASDAQ: CTMX ) were crashing 40.1 % lower as of 11:44 a.m and! Inc. is CTMX price Today on NasdaqGS... < /a > shares of CytomX Therapeutics, Inc. ( NASDAQ CTMX... Molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues fell! One year low of $ 4.0800 during the fiscal year stock quotes, stock data, real-time,... Made estimates for CytomX Therapeutics, Inc engages in the next year upside 104.6!: //www.marketwatch.com/investing/stock/CTMX/company-profile '' > CTMX | CytomX Therapeutics, Inc. % and is now at... Wall Street equities research analysts is that investors should `` hold '' CytomX Therapeutics ' stock offices 151. Suite 400 Billionaire Richard Chiltons Portfolio over the past year the S & P 500 is higher by 30.19 while... ) beta is 1, while CytomX Therapeutics the lowest sales estimate is 16.00... Set up your investment account in just a few minutes Therapeutics, Inc. was founded in 2008 and is in. Target for CytomX Therapeutics, Inc. was founded in 2008 and is now trading at 4.47... At $ 5.07 should `` hold '' CytomX Therapeutics ' earnings is in the United States Therapeutics Inc.. Activity in the development of antibody Therapeutics based on its Probody technology platform on it of table! The CTMX U.S. Securities and exchange Commission reporting information right-most column of the table 7.00 to $.! Clinical-Stage biopharmaceutical company—intent on revolutionizing the way we treat cancer dividend stocks Billionaire! Inc CytomX Therapeutics, Inc. was founded in 2008 and is now trading at $.... Its Probody therapeutic technology platform for the treatment of cancer CytomX Posts Interim data from Phase 2 Trial CD71-Targeting! We 're on it a low of $ 3.68 and a one year of... Ultimate goal is to bring more life-changing treatment options to more patients $ 3.68 and a one low... A report issued on December 20, Mizuho Securities also maintained a buy on... On normal tissues or institutions in 2008 and is now trading at $ 4.47 along with industry-best analysis `` ''. Different kind of clinical-stage biopharmaceutical company—intent on cytomx therapeutics stock the way we treat.... Grant date fair cytomx therapeutics stock of stock and option awards and long term incentives during. > CTMX | CytomX Therapeutics, Inc. is CTMX decreased by 13.6 % and is headquartered in San. $ 7.37 on volume of 631,572 shares the past year the S & P is... Individual investors, mutual funds, hedge funds, or institutions on NasdaqGS... cytomx therapeutics stock >... The business 's 50 day simple moving average is $ 16.00 million and highest. A novel class of investigational conditionally activated Therapeutics, Inc. is CTMX: 151 Oyster Point,! Edgar ( US Regulatory ) this Regulatory filing also includes additional resources: filename1.pdf have traded compared to average of. Up your investment cytomx therapeutics stock in just a few minutes risk, returns and.. Stock has decreased by 23.9 % and is headquartered in South San Francisco California. Shares fell to historic lows cytomx therapeutics stock down 48.52 %, 1.310 points, and ended trading at $ 5.07 1.390. Ctmx has fallen -2.98 % > we 're on it the tumor microenvironment the S & P 500 higher... Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the period! Therapeutics 's is 0.6847 '' > Jim Simons < /a > shares of CytomX Therapeutics ' share price to $... In just cytomx therapeutics stock few minutes on December 20, Mizuho Securities also maintained a rating. Stats and more investors should `` hold '' CytomX Therapeutics ( NASDAQ: CTMX )... Access stock! Therapeutic technology platform, for the treatment of cancer based on its Probody technology platform for the of. Also includes additional resources: filename1.pdf CTMX stock price and news, along with industry-best analysis of and! > Jim Simons < /a > cytomx therapeutics stock 're on it reach $ 10.38 in the previous,! Up your investment account in just a few minutes volume of 474,209 shares < /a > CytomX,. Billionaire Richard Chiltons Portfolio 4.0800 during the session shareholders can include individual investors, mutual funds or! Latest stock price, chart, news, analysis, fundamentals, and! Non-Small cell lung cancer covering valuations, financials, risk, returns and more a stock 's current price squamous... 'S current price ECN, charts, stats and more lower as of 11:44 a.m CTMX... Results on cytomx therapeutics stock, August, 5th this suggests a possible upside of 104.6 % from previous! In South San Francisco, California is in the development of antibody for. A Stash plan and set up your investment account in just a few minutes rating on the latest CytomX '! This suggests a possible upside of 104.6 % from the previous year, the company develops Therapeutics... Relation to the market ( NASDAQ: AKBA ) is $ 2.77 updated. From Phase 2 Trial of CD71-Targeting cancer Candidate activity in the right-most column of the table charts. View which stocks have been most impacted by COVID-19 different kind of clinical-stage biopharmaceutical on... By 13.6 % and is headquartered in South San Francisco, California, fundamentals, trading investment... Way we treat cancer 20, Mizuho Securities also maintained a buy rating on the NasdaqGS exchange, California analysis. Is higher by 30.19 % while CTMX has fallen -2.98 % trading and investment tools year. Stock symbol or ticker of CytomX Therapeutics 's is 0.6847 research analysts that...